12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Boehringer Ingelheim preclinical data

In a rat model of bleeding, a potential dabigatran antidote led to dose-dependent decrease in blood loss induced by supratherapeutic levels of Pradaxa dabigatran. Data were presented at the American Heart Association...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >